ClinicalTrials.gg
CompletedNCT01879319Updated Nov 30, 2022Results posted

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

A Phase 3 interventional study of Evolocumab AMD and Evolocumab AI/pen in Primary Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Amgen. Completed at 27 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.

Enrollment
22nd of 36
164 · median 308
Started
2013
with 10 others
Phase 3
22 of 36
none open now
Registered
17th of 36
by date
Lead sponsor
30 of 36
Amgen

Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 22nd largest by enrollment, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 17th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing evolocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).

03

Conditions studied

  • Primary Hypercholesterolemia
  • Mixed Dyslipidemia

Keywords

  • LDL-C, triglycerides, high cholesterol
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fasting LDL-C at screening > 85 mg/dL
  • Fasting triglycerides less than or equal to 400 mg/dL (4.5 mmol/L)

Exclusion criteria

Exclusion Criteria:

  • (NYHA) III or IV heart failure
  • Uncontrolled cardiac arrhythmia
  • Uncontrolled hypertension
  • Type 1 diabetes or poorly controlled type 2 diabetes
  • Uncontrolled hypothyroidism or hyperthyroidism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    Evolocumab AMD

    Participants received evolocumab 420 mg once a month subcutaneously using an automated mini-doser (AMD) (one 3.5 mL injection) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.

    Biological: Evolocumab AMD

  • Experimental
    Evolocumab AI/pen

    Participants received evolocumab 420 mg once a month subcutaneously using an autoinjector/pen (AI/pen) (three 1.0 mL injections) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.

    Biological: Evolocumab AI/pen

Interventions

  • BiologicalEvolocumab AMD

    Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.

    Also known as: AMG 145, Repatha

  • BiologicalEvolocumab AI/pen

    Drug page: Evolocumab

    Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.

    Also known as: AMG-145, Repatha

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 8

    Self-administration of evolocumab was assessed by a telephone interview at Weeks 4 and 8. Each participant was asked about all attempted injection(s) and if the injection was administered in part, full, or none at all. Results only include full administrations that occurred inside the prespecified visit window.

    Time frame: Weeks 4 and 8

Secondary outcomes

  1. Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

07

Results

Posted Dec 23, 2015

Participant flow

Eligible patients were men and women ≥ 18 and ≤ 80 years of age with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 85 mg/dL, fasting triglycerides ≤ 400 mg/dL and on a stable dose of a statin with or without ezetimibe for at least 4 weeks. The first patient enrolled on 11 July 2013 and the last patient enrolled on 20 September 2013.

Participant flow — Overall Study
MilestoneEvolocumab AMDEvolocumab AI/Pen
Started8282
Received treatment8282
Completed8077
Not completed25
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up15

Outcome measures

PrimaryPercentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 8

Self-administration of evolocumab was assessed by a telephone interview at Weeks 4 and 8. Each participant was asked about all attempted injection(s) and if the injection was administered in part, full, or none at all. Results only include full administrations that occurred inside the prespecified visit window.

Time frame:
Weeks 4 and 8
Reported as:
Number · Percentage of participants
Percentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 8
Percentage of participantsEvolocumab AMDEvolocumab AI/Pen
Percentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 893.9 (86.5 to 97.4)91.5 (83.4 to 95.8)
Statistical analysis
  • Evolocumab AMD vs Evolocumab AI/Pen · Treatment difference: -2.4 · 95% CI -11.2 to 6.1
SecondaryPercent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
percent changeEvolocumab AMDEvolocumab AI/Pen
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12-67.9 ± 2.4-64.5 ± 2.4
Statistical analysis
  • Evolocumab AMD vs Evolocumab AI/Pen · Ls mean treatment difference: 3.4 · 95% CI -2.9 to 9.7

Adverse events

Collected over From first dose of study drug until 28 days after last study drug administration (up to 12 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Evolocumab AMD—0/82 (0%)0/82 (0%)
Evolocumab AI/Pen—1/82 (1.2%)0/82 (0%)
Most frequent serious events
Most frequent serious events
EventEvolocumab AMDEvolocumab AI/Pen
Deep vein thrombosisVascular disorders0/821/82

Baseline characteristics

Full analysis set (all randomized participants who received at least 1 dose of study drug).

Age, Continuous
Age, Continuous(years)Evolocumab AMDEvolocumab AI/PenTotal
Mean60.1 ± 10.559.2 ± 10.059.7 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Evolocumab AMDEvolocumab AI/PenTotal
Female393978
Male434386
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Evolocumab AMDEvolocumab AI/PenTotal
American Indian or Alaska Native112
Asian437
Black or African American628
Native Hawaiian or Other Pacific Islander000
White6975144
Other202
Mixed Race011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Evolocumab AMDEvolocumab AI/PenTotal
Hispanic or Latino4610
Not Hispanic or Latino7876154
Stratification Factor: LDL-C Level
Stratification Factor: LDL-C Level(participants)Evolocumab AMDEvolocumab AI/PenTotal
< 130 mg/dL6059119
≥ 130 mg/dL222345
LDL-C Concentration
LDL-C Concentration(mg/dL)Evolocumab AMDEvolocumab AI/PenTotal
Mean115.3 ± 27.0117.3 ± 23.9116.3 ± 25.4
08

Study locations

27 sites
  • Research Site
    Phoenix, Arizona 85020, United States
  • Research Site
    Encino, California 91436, United States
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Tustin, California 92780, United States
  • Research Site
    Ventura, California 93003, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Saint Augustine, Florida 32086, United States
  • Research Site
    Atlanta, Georgia 30328, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    Lexington, Kentucky 40504, United States
  • Research Site
    Lewiston, Maine 04240, United States
  • Research Site
    Ayer, Massachusetts 01432, United States
  • Research Site
    Manlius, New York 13104, United States
  • Research Site
    Cadiz, Ohio 43907, United States
  • Research Site
    Marion, Ohio 43302, United States
  • Research Site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Lansdale, Pennsylvania 19446, United States
  • Research Site
    Jackson, Tennessee 38305, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Austin, Texas 78731, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Burnaby, British Columbia V5G 1T4, Canada
  • Research Site
    London, Ontario N5W 6A2, Canada
  • Research Site
    Sarnia, Ontario N7T 4X3, Canada
  • Research Site
    Toronto, Ontario M9V 4B4, Canada
  • Research Site
    Pointe-Claire, Quebec H9R 3J1, Canada
09

References and documents

Publications

  • Boccara F, Dent R, Ruilope L, Valensi P. Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia. Adv Ther. 2017 Aug;34(8):1876-1896. doi: 10.1007/s12325-017-0586-8. Epub 2017 Jul 17. PubMed 28717862 ↗
  • Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. PubMed 29353350 ↗
  • Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1. PubMed 28249876 ↗
  • Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, Lopez JAG, Banach M. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. J Am Heart Assoc. 2020 Mar 3;9(5):e014129. doi: 10.1161/JAHA.119.014129. Epub 2020 Mar 2. PubMed 32114889 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Nov 2013, 4 months.

Results were first posted in Dec 2015, 2 years 1 month after primary completion. A results delay was requested in May 2014.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 4 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2013
First posted
Jun 17, 2013
StartActual
Jul 11, 2013
Primary completionActual
Nov 15, 2013
Results delay requested
May 2, 2014
Results first posted
Dec 23, 2015
Last update
Nov 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01879319
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 17, 2013
Start date
Jul 11, 2013
Primary completion
Nov 15, 2013
Results posted
Dec 23, 2015
Last update
Nov 30, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion